Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Bor, Jacob ^a,b,c   Ahmed, Shahira ^a,c   Fox, Matthew P ^a,c   Rosen, Sydney ^a,c   Meyer Rath, Gesine ^a,c   Katz, Ingrid T ^d,e,f   Tanser, Frank ^b   Pillay, Deenan ^b,g   Bärnighausen, Till ^b,h,i  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIFFERENTIAL THRESHOLD; EMPIRICAL RESEARCH; FEMALE; HEALTH CARE POLICY; HEALTH INSURANCE ELIGIBILITY; HEALTH PROGRAM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PROGRAM COST EFFECTIVENESS; SIMULATION; SOUTH AFRICA; THERAPY EFFECT; TREATMENT OUTCOME; HIV INFECTIONS; IMMUNOLOGY; PATIENT SELECTION; REGRESSION ANALYSIS; THEORETICAL MODEL; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; PATIENT SELECTION; REGRESSION ANALYSIS; SOUTH AFRICA; YOUNG ADULT;

EID: 85020804760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178249     Document Type: Article

References (42)

1. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493-505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103
3. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373: 795-807. https://doi.org/10.1056/ NEJMoa1506816 PMID: 26192873
4. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373: 808-22. https://doi.org/10.1056/ NEJMoa1507198 PMID: 26193126
5. Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: A systematic review. J Int AIDS Soc. 2012; 15: 17383. https://doi.org/10.7448/IAS.15.2.17383 PMID: 23199799
6. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: A systematic review. PLoS Medicine. 2011.
7. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: Systematic review and metaanalysis. Trop Med Int Heal. 2012; 17: 1509-1520.
8. Bor J, Moscoe E, Mutevedzi P, Newell M-L, Bärnighausen T. Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology. 2014; 25: 729-737. https://doi.org/ 10.1097/EDE.0000000000000138 PMID: 25061922
9. Bor J, Moscoe E, Bärnighausen T. When to Start HIV Treatment: Evidence from a Regression Discontinuity Study in South Africa. Population Association of America Annual Meeting. San Diego, CA; 2015. Available: http://paa2015.princeton.edu/abstracts/151012
10. Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA, et al. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015; 19: 704-14. https://doi.org/10.1007/s10461-014-0920-y PMID: 25304330
11. Motsoaledi A. Health Dept Budget Vote Speech 2016/17 [Internet]. Department of Health, South Africa; 2016. Available: http://www.gov.za/speeches/debate-health-budget-vote-national-assembly-10-may-2016-dr-aaron-motsoaledi-minister-health
12. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012; 9: e1001245. https://doi.org/10.1371/journal. pmed.1001245 PMID: 22802730
13. Pillay Y. Operational and programmatic considerations in scaling up ART. IAS 2013: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia; 2013.
14. Health ND of. The South African Antiretroviral Treatment Guidelines. South Africa. 2013;
15. South African National Ministry of Health. The South African Antiretroviral Treatment Guidelines [Internet]. 2010.
16. National Department of Health. National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV and the Management of HIV in Children, Adolescents and Adults [Internet]. 2015.
17. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol. 2011; 40: 318-26. https://doi.org/10.1093/ije/ dyp402 PMID: 20154009
18. Mutevedzi PC, Lessells RJ, Newell M-L. Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa. Trop Med Int Health. England; 2013; 18: 934-941. https://doi.org/10.1111/tmi.12135 PMID: 23731253
19. Plazy M, Dabis F, Naidu K, Orne-Gliemann J, Barnighausen T, Dray-Spira R. Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infect Dis. England; 2015; 15: 452. https://doi.org/10.1186/s12879-015-1207-2 PMID: 26497054
20. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F, Newell M-L. Continuum in HIV care from entry to ART initiation in rural KwaZulu-Natal, South Africa. Trop Med Int Health. 2014; 19: 680-689. https://doi. org/10.1111/tmi.12301 PMID: 24654990
21. Fox MP, Larson B, Rosen S. Defining retention and attrition in pre-antiretroviral HIV care: Proposals based on experience in Africa. Trop Med Int Heal. 2012; 17: 1235-1244.
22. Moscoe E, Bor J, Bärnighausen T. Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: A review of current and best practice. J Clin Epidemiol. 2015; 68: 122-133. https://doi.org/10.1016/j.jclinepi.2014.06.021 PMID: 25579639
23. O'Keeffe AG, Geneletti S, Baio G, Sharples LD, Nazareth I, Petersen I. Regression discontinuity designs: An approach to the evaluation of treatment efficacy in primary care using observational data. Br Med J. 2014; 349: g5293.
24. Imbens GW, Lemieux T. Regression discontinuity designs: A guide to practice. J Econom. 2008; 142: 615-635.
25. Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit. 2010; 48: 281-355.
26. Bor J, Moscoe E, Bärnighausen T. Three approaches to causal inference in regression discontinuity designs. Epidemiology. 2015; 26: e28-30.
27. Rubin D. Assignment to treatment group on the basis of a covariate. J Educ Behav Stat. 1977; 2: 1-26.
28. Hahn J, Todd P, Van der Klaauw W. Identification and estimation of treatment effects with a regressiondiscontinuity design. Econometrica. 2001; 69: 201-209.
29. Imbens GW, Kalyanaraman K. Optimal bandwidth choice for the regression discontinuity estimator. Rev Econ Stud. 2011; 79: 933-959.
30. Meyer-Rath G, Pillay Y, Blecher M, Brennan A, Long L, Johnson L, et al. Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa 2010 to 2017. Abstract no. WEAE0201. International AIDS Conference. Vienna, Austria; 2010.
31. Chiu C, Bor J, Ahmed S, Katz IT, Fox MP, Rosen S, et al. HIV treatment refusal in patients with high CD4 counts: evidence from demographic surveillance in rural KwaZulu-Natal. (Poster). International AIDS Conference. Durban, South Africa; 2016.
32. Chimbindi N, Bor J, Newell M-L, Tanser F, Baltussen R, Hontelez J, et al. Time and Money: The True Costs of Health Care Utilization for Patients Receiving "Free" HIV/Tuberculosis Care and Treatment in Rural KwaZulu-Natal. J Acquir Immune Defic Syndr. 2015; 70: e52-60. https://doi.org/10.1097/QAI. 0000000000000728 PMID: 26371611
33. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016; 13: e1002015. https://doi.org/10.1371/journal.pmed.1002015 PMID: 27163694
34. Bor J, Fox MP, Rosen S, Venkataramani A, Tanser F, Pillay D, et al. The Real-World Impact of CD4-Eligibility Criteria on Retention in HIV Care. CROI. Boston, MA; 2016.
35. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low-and middle-income countries: Systematic review and meta-analysis 2008-2013. J Acquir Immune Defic Syndr. 2015; 69: 98-108. https://doi.org/10.1097/QAI.0000000000000553 PMID: 25942461
36. Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sanne I. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. United States; 2014; 9: e110252. https:// doi.org/10.1371/journal.pone.0110252 PMID: 25330087
37. Clouse K, Hanrahan CF, Bassett J, Fox MP, Sanne I, Van Rie A. Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. England; 2014; 19: 1411-1419. https://doi.org/10.1111/tmi.12387 PMID: 25244155
38. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating ART at a Patient's First Clinic Visit: The RapIT Randomized Trial. CROI. Boston, MA; 2016.
39. Bor J, Moscoe E, Mutevedzi P, Newell M-L, Bärnighausen T. Regression discontinuity designs in epidemiology: Causal inference without randomized trials. Epidemiology. 2014; 25: 729-737. https://doi.org/ 10.1097/EDE.0000000000000138 PMID: 25061922
40. Venkataramani AS, Bor J, Jena AB. Regression discontinuity designs in healthcare research. BMJ. 2016; 352: i1216. Available: http://www.ncbi.nlm.nih.gov/pubmed/26977086 https://doi.org/10.1136/ bmj.i1216 PMID: 26977086
41. Meyer-Rath G, Over M. HIV treatment as prevention: Modelling the cost of antiretroviral treatment-State of the art and future directions. PLoS Med. Public Library of Science; 2012; 9: e1001247. https:// doi.org/10.1371/journal.pmed.1001247 PMID: 22802731
42. Bor J, Nattey C, Maughan-Brown B, MacLeod W, Maskew M, Carmona S, et al. Rising CD4 counts at clinical presentation: evidence from a novel national database in South Africa. 21st International AIDS Conference, July 18-22, 2016. Durban, South Africa; p. 782.